Sex/Age (yrs) Year of SSc Onset/disease duration at skin biopsy (years) MRSS/score at skin biopsy Autoantibodies Lung involvment HRCT/PFT Heart involvement /Scleroderma renal crisis Raynaud’s phenomenon/ Digital ulcers
F/46 2010/2 12/2 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/21 2009/3 13/1 ANA/Scl-70 Normal/Normal Normal/No Yes/Yes
F/31 2011/1 13/2 ANA/Scl-70 Normal/Normal Normal/No Yes/Yes
F/36 2010/2 11/2 ANA/Scl-70 Normal/Normal  PAH/No Yes/Yes
M/20 2010/2 11/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/41 2010/2 15/2 ANA/Scl-70 Normal/Normal Normal/No No/No
F/30 2010/2 10/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/21 2010/2 09/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/31 2009/3 14/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/42 2009/3 16/2 ANA/Scl-70 Fibrosis/Normal Normal/No Yes/No
MRSS: Modified Rodnan Skin Thickness Score (maximum possible score 51); HRCT: High Resolution Computed Tomography; PFT: Pulmonary Function Test; ANA: Antinuclear Antibodies; ACA: Anti-Centromere Antibodies; Scl-70 anti topoisomerase; PAH: Pulmonary Arterial Hypertension.
Table 1: Clinical and demographic features of the 10 diffuse SSc patients.